$6.01
Genfit is a biotechnology business based in the US. Genfit shares (GNFT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.95 – a decrease of 2.7% over the previous week. Genfit employs 169 staff and has a trailing 12-month revenue of around $80.5 million.
Our top picks for where to buy Genfit stock
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Genfit stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – GNFT. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Genfit stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Genfit stock price (NASDAQ: GNFT)
Use our graph to track the performance of GNFT stocks over time.Genfit shares at a glance
Latest market close | $5.95 |
---|---|
52-week range | $2.97 - $6.13 |
50-day moving average | $4.65 |
200-day moving average | $4.11 |
Wall St. target price | N/A |
PE ratio | 14.4146 |
Dividend yield | N/A |
Earnings per share (TTM) | $0.41 |
Is it a good time to buy Genfit stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Genfit price performance over time
Historical closes compared with the close of $5.94 from 2024-10-18
1 week (2024-10-15) | 0.51% |
---|---|
1 month (2024-09-20) | 22.73% |
3 months (2024-07-22) | 35.93% |
6 months (2024-04-22) | 62.30% |
1 year (2023-10-20) | 94.44% |
---|---|
2 years (2022-10-21) | 53.09% |
3 years (2021-10-22) | 65.00% |
5 years (2019-10-22) | 14.5 |
Is Genfit stock undervalued or overvalued?
Valuing Genfit stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Genfit's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Genfit's P/E ratio
Genfit's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Genfit shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Genfit's EBITDA
Genfit's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $21.9 million.
The EBITDA is a measure of a Genfit's overall financial performance and is widely used to measure a its profitability.
Genfit financials
Revenue TTM | $80.5 million |
---|---|
Operating margin TTM | 51% |
Gross profit TTM | $26.2 million |
Return on assets TTM | 6.51% |
Return on equity TTM | 25.91% |
Profit margin | 27.68% |
Book value | $1.96 |
Market Capitalization | $294.9 million |
TTM: trailing 12 months
Genfit share dividends
We're not expecting Genfit to pay a dividend over the next 12 months.
Genfit share price volatility
Over the last 12 months, Genfit's shares have ranged in value from as little as $2.97 up to $6.13. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Genfit's is 1.095. This would suggest that Genfit's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Genfit overview
Genfit S. A. , a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.
Frequently asked questions
nullWhat percentage of Genfit is owned by institutions?
Currently 0.153% of Genfit shares are held by institutions. How many people work for Genfit?
Latest data suggests 169 work at Genfit. When does the fiscal year end for Genfit?
Genfit's fiscal year ends in December. Where is Genfit based?
Genfit's address is: Parc EurasantE, Loos, France, 59120 What is Genfit's ISIN number?
Genfit's international securities identification number is: US3722791098 What is Genfit's CUSIP number?
Genfit's Committee on Uniform Securities Identification Procedures number is: 372279109
More guides on Finder
-
Fundamental Analysis
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
eToro review 2024: Commission-free social trading and investing
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
-
Titan Review 2024: Wealth Management With a No-Advisory-Fee Robo-Advisor
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
-
Public.com Review 2024: No-Fee Options, With Rebates
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
-
How to trade options
Read our beginner’s guide to trading options in the US.
Ask a question